Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 6/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GSK3B | P49841 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22433005 | 0.87 | POLB (0.44) | POLBALDH1A1CYP1A2CYP2D6MEN1 | |
| SCHEMBL19341279 | 0.84 | POLB (0.41) | PLK1POLBKDM4EALDH1A1TDP1 | |
| SCHEMBL15988656 | 0.81 | SMN1; SMN2 (0.41) | PLK1SMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL15979639 | 0.77 | PLK1 (0.35) | AKR1B1PLK1SMN1; SMN2POLBKDM4E | |
| SCHEMBL19341276 | 0.77 | PLK1 (0.37) | PLK1SMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL19346092 | 0.73 | SMN1; SMN2 (0.42) | PLK1SMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL15988653 | 0.71 | POLB (0.44) | PLK1POLBKDM4EALDH1A1TDP1 | |
| SCHEMBL24192680 | 0.71 | POLB (0.44) | SMN1; SMN2POLBALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL21036173 | 0.71 | POLB (0.44) | SMN1; SMN2POLBALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL14040992 | 0.70 | SMN1; SMN2 (0.41) | PLK1SMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2018-07-12 | — | — | US | disclosed |
| US-9795550-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | SAMUMED, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-9533976-B2 | γ-diketones as WNT/β-catenin signaling pathway activators | SAMUMED, LLC (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2016-07-21 | — | — | US | disclosed |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193244-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | AKR1B1 939/4885PLK1 1039/4885SMN1; SMN2 4122/4885 |
| US-20160206540-A1 | GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES | GLA, DGKG, DGKA | AKR1B1 939/4885PLK1 1039/4885SMN1; SMN2 4122/4885 |
| US-11839679-B2 | Gamma-diketones for treatment and prevention of aging skin and wrinkles | DGKG, DGKA, DNER | AKR1B1 1283/4885PLK1 655/4885SMN1; SMN2 4631/4885 |
| US-20140243349-A1 | GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS | GSK3A, GSK3B, WNT1 | AKR1B1 1213/4885PLK1 397/4885SMN1; SMN2 1829/4885 |
| US-11673885-B2 | γ-diketones as Wnt/β-catenin signaling pathway activators | GSK3A, GSK3B, WNT1 | AKR1B1 1194/4885PLK1 376/4885SMN1; SMN2 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.